Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PLK1 | P53350 | 4/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CRY1 | Q16526 | 5/20 | 0.31 |
| ▸ | CRY2 | Q49AN0 | 5/20 | 0.31 |
| ▸ | PER2 | O15055 | 3/20 | 0.31 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6267035 | 0.95 | CYP2C9 (0.90) | CYP2C9NR1I2MAPK1HSD17B10PLK1 | |
| SCHEMBL6688874 | 0.94 | CYP2C9 (0.88) | CYP2C9NR1I2MAPK1HSD17B10PLK1 | |
| SCHEMBL6232681 | 0.93 | CYP2C9 (0.88) | CYP2C9NR1I2MAPK1HSD17B10PLK1 | |
| SCHEMBL6736116 | 0.91 | CYP2C9 (0.84) | CYP2C9NR1I2MAPK1HSD17B10HIF1A | |
| SCHEMBL6732550 | 0.91 | CYP2C9 (0.83) | CYP2C9NR1I2MAPK1HSD17B10PLK1 | |
| SCHEMBL6285555 | 0.91 | CYP2C9 (0.83) | CYP2C9NR1I2MAPK1HSD17B10PLK1 | |
| SCHEMBL6684550 | 0.90 | CYP2C9 (0.82) | CYP2C9NR1I2MAPK1HSD17B10HIF1A | |
| SCHEMBL6235993 | 0.90 | CYP2C9 (0.82) | CYP2C9NR1I2MAPK1HSD17B10PLK1 | |
| SCHEMBL6736069 | 0.90 | CYP2C9 (0.82) | CYP2C9NR1I2MAPK1HSD17B10PLK1 | |
| SCHEMBL6692294 | 0.89 | CYP2C9 (0.80) | CYP2C9NR1I2MAPK1HSD17B10PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1401443-A4 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORP (US) | 2005-10-26 | — | — | EP | claimed |
| US-20040147739-A1 | Novel anti-infectives | SMITHKLINE BEECHAM CORPORATION | 2004-07-29 | — | — | US | claimed |
| EP-1401443-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-03-31 | — | — | EP | claimed |
| WO-2002098424-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-12-12 | — | — | WO | claimed |
| US-20070232644-A1 | 1-(2,4-difluorobenzyl)-N-hydroxy-3-{[3-(methylsulfonyl)pyrrolidin-1-yl]methyl}-1H-pyrrolo[2,3-c]pyridine-5-carboxamide;acquired immunodeficiency syndrome (\"AIDS\"), and AIDS related complex (\"ARC\") | PFIZER INC. | 2007-10-04 | — | — | US | disclosed |
| US-20070232644-A1 | 1-(2,4-difluorobenzyl)-N-hydroxy-3-{[3-(methylsulfonyl)pyrrolidin-1-yl]methyl}-1H-pyrrolo[2,3-c]pyridine-5-carboxamide;acquired immunodeficiency syndrome (\"AIDS\"), and AIDS related complex (\"ARC\") | PFIZER INC. | 2007-10-04 | — | — | US | disclosed |
| EP-1401443-A4 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORP (US) | 2005-10-26 | — | — | EP | disclosed |
| US-20040147739-A1 | Novel anti-infectives | SMITHKLINE BEECHAM CORPORATION | 2004-07-29 | — | — | US | disclosed |
| WO-2004052313-A2 | ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-06-24 | — | — | WO | disclosed |
| EP-1401443-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-03-31 | — | — | EP | disclosed |
| WO-2002098424-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147739-A1 | Novel anti-infectives | RPL5, RPL7, RPL35 | CYP2C9 1218/4885NR1I2 1798/4885MAPK1 3699/4885 |
| US-20070232644-A1 | 1-(2,4-difluorobenzyl)-N-hydroxy-3-{[3-(methylsulfonyl)pyrrolidin-1-yl]methyl}-1H-pyrrolo[2,3-c]pyridine-5-carboxamide;acquired immunodeficiency syndrome (\"AIDS\"), and AIDS related complex (\"ARC\") | AP1M1, AP1G1, AP3B1 | CYP2C9 3503/4885NR1I2 1539/4885MAPK1 1092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.